Prostate cancer (metastatic, hormone relapsed, not treated with chemotherapy) - abiraterone acetate (with prednisolone): evaluation report
Contents:
01. NICE's response to comments on the Appraisal Consultation Document (ACD)
02. Consultee comments on the ACD - Janssen
03 Consultee comments on the ACD - Prostate Cancer UK
04 Consultee comments on the ACD - TACKLE
05 Consultee comments on the ACD - BAUN
06 Consultee comments on the ACD - BUG
07 Consultee comments on the ACD - NCRI-RCP-RCR-ACP-JCCO
08 Commentator comments on the ACD - DH
09 Commentator comments on the ACD - Sanofi
10 Commentator comments on the ACD - ICR
11 Public comments on the ACD received via the NICE website
12 Evidence Review Group Addendum
13 Additional Document from the manufacturer Janssen
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report. It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal.
|
Prostate cancer (metastatic, hormone relapsed, not treated with chemotherapy) - abiraterone acetate (with prednisolone): evaluation report
15 August 2014 (2.5 Mb 25 sec) |
This page was last updated: 14 August 2014